TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - MODERNA | Market Closed - Boerse Frankfurt Warrants 03:45:50 2024-07-11 pm EDT | ||
| 4.18 EUR | -11.63% |
|
| Current month | -9.91% | ||
| 1 month | +112.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 4.18 | -11.63% |
| 24-07-10 | 4.73 | -2.47% |
| 24-07-09 | 4.85 | -0.21% |
| 24-07-08 | 4.86 | +4.74% |
| 24-07-05 | 4.64 | +1.09% |
Real-time Boerse Frankfurt Warrants
Last update July 11, 2024 at 03:45 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SW6WZY |
| ISIN | DE000SW6WZY9 |
| Date issued | 2024-05-27 |
| Strike | 167.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.29 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.03 € |
|---|---|
| Lowest since issue | 0.053 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.8
USD
Average target price
145.9
USD
Spread / Average Target
+18.79%
- Stock Market
- Certificates
- Certificat
